)
Kanti Thirumoorthy
Vice President, Cell Therapy Development & Manufacturing,
AstraZeneca
United States
Dr. Thirumoorthy has 20 years of experience in the pharmaceutical industry, including in cell therapies, with expertise in technical operations, chemistry, Manufacturing and Control (CMC), quality control and quality assurance/compliance.
Before joining AstraZeneca, she spent 3 years at Neogene building the Technical operations team of experienced leaders to handle TCR products from pre-IND onwards. She spent six years at Kite Pharma, where she was part of the team to take Yescarta and Tecartus from pre-IND to BLA and launch. Prior to Kite Pharma, she was Principal, Quality Control and Assurance, at Quality Systems Solutions. She also held positions in Quality Assurance and Quality Control. She began her career in biopharma as a Senior Scientist/Group Leader, Research & Development, at PPD Development.
Dr. Thirumoorthy earned a B.Sc. in chemistry from the University of Madras in India, an M.S. and Ph.D. in chemistry from the Indian Institute of Technology in Madras and was a Post-Doctoral Research Associate at the University of Illinois in Chicago and Urbana.
Before joining AstraZeneca, she spent 3 years at Neogene building the Technical operations team of experienced leaders to handle TCR products from pre-IND onwards. She spent six years at Kite Pharma, where she was part of the team to take Yescarta and Tecartus from pre-IND to BLA and launch. Prior to Kite Pharma, she was Principal, Quality Control and Assurance, at Quality Systems Solutions. She also held positions in Quality Assurance and Quality Control. She began her career in biopharma as a Senior Scientist/Group Leader, Research & Development, at PPD Development.
Dr. Thirumoorthy earned a B.Sc. in chemistry from the University of Madras in India, an M.S. and Ph.D. in chemistry from the Indian Institute of Technology in Madras and was a Post-Doctoral Research Associate at the University of Illinois in Chicago and Urbana.
Sessions